<table frame="hsides" id="wherry1138991684802" xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><caption>Table 1Major Outcomes of the NSABP B-24 Trial</caption>
<colgroup>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
</colgroup>
<thead>
<tr><td valign="top"><paragraph><content stylecode="bold">Type of Event</content></paragraph></td><td colspan="2" valign="top"><paragraph><content stylecode="bold">Lumpectomy, radiotherapy and placebo</content></paragraph></td><td colspan="2" valign="top"><paragraph><content stylecode="bold">Lumpectomy, radiotherapy, and NOLVADEX</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">RR</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">95% CI Limits</content></paragraph></td></tr>
<tr><td valign="top"></td><td valign="top"><paragraph><content stylecode="bold">No. of events</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">Rate per 1000 women per year</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">No. of events</content></paragraph></td><td valign="top"><paragraph><content stylecode="bold">Rate per 1000 women per year</content></paragraph></td><td valign="top"></td><td valign="top"></td></tr>
</thead>
<tbody>
<tr><td valign="top"><paragraph><content stylecode="bold">Invasive breast cancer (Primary endpoint)</content></paragraph></td><td valign="top"><paragraph>74</paragraph></td><td valign="top"><paragraph>16.73</paragraph></td><td valign="top"><paragraph>44</paragraph></td><td valign="top"><paragraph>9.60</paragraph></td><td valign="top"><paragraph>0.57</paragraph></td><td valign="top"><paragraph>0.39 to 0.84</paragraph></td></tr>
<tr><td valign="top"><paragraph>-Ipsilateral</paragraph></td><td valign="top"><paragraph>47</paragraph></td><td valign="top"><paragraph>10.61</paragraph></td><td valign="top"><paragraph>27</paragraph></td><td valign="top"><paragraph>5.90</paragraph></td><td valign="top"><paragraph>0.56</paragraph></td><td valign="top"><paragraph>0.33 to 0.91</paragraph></td></tr>
<tr><td valign="top"><paragraph>-Contralateral</paragraph></td><td valign="top"><paragraph>25</paragraph></td><td valign="top"><paragraph>5.64</paragraph></td><td valign="top"><paragraph>17</paragraph></td><td valign="top"><paragraph>3.71</paragraph></td><td valign="top"><paragraph>0.66</paragraph></td><td valign="top"><paragraph>0.33 to 1.27</paragraph></td></tr>
<tr><td valign="top"><paragraph>-Side undetermined</paragraph></td><td valign="top"><paragraph>2</paragraph></td><td valign="top"><paragraph>--</paragraph></td><td valign="top"><paragraph>0</paragraph></td><td valign="top"><paragraph>--</paragraph></td><td valign="top"><paragraph>--</paragraph></td><td valign="top"></td></tr>
<tr><td colspan="2" valign="top"><paragraph><content stylecode="bold">Secondary Endpoints</content></paragraph></td><td colspan="5" valign="top"></td></tr>
<tr><td valign="top"><paragraph>DCIS</paragraph></td><td valign="top"><paragraph>56</paragraph></td><td valign="top"><paragraph>12.66</paragraph></td><td valign="top"><paragraph>41</paragraph></td><td valign="top"><paragraph>8.95</paragraph></td><td valign="top"><paragraph>0.71</paragraph></td><td valign="top"><paragraph>0.46 to 1.08</paragraph></td></tr>
<tr><td valign="top"><paragraph>-Ipsilateral</paragraph></td><td valign="top"><paragraph>46</paragraph></td><td valign="top"><paragraph>10.40</paragraph></td><td valign="top"><paragraph>38</paragraph></td><td valign="top"><paragraph>8.29</paragraph></td><td valign="top"><paragraph>0.88</paragraph></td><td valign="top"><paragraph>0.51 to 1.25</paragraph></td></tr>
<tr><td valign="top"><paragraph>-Contralateral</paragraph></td><td valign="top"><paragraph>10</paragraph></td><td valign="top"><paragraph>2.26</paragraph></td><td valign="top"><paragraph>3</paragraph></td><td valign="top"><paragraph>0.65</paragraph></td><td valign="top"><paragraph>0.29</paragraph></td><td valign="top"><paragraph>0.05 to 1.13</paragraph></td></tr>
<tr><td valign="top"><paragraph>All Breast Cancer Events</paragraph></td><td valign="top"><paragraph>129</paragraph></td><td valign="top"><paragraph>29.16</paragraph></td><td valign="top"><paragraph>84</paragraph></td><td valign="top"><paragraph>18.34</paragraph></td><td valign="top"><paragraph>0.63</paragraph></td><td valign="top"><paragraph>0.47 to 0.83</paragraph></td></tr>
<tr><td valign="top"><paragraph>-All ipsilateral events</paragraph></td><td valign="top"><paragraph>96</paragraph></td><td valign="top"><paragraph>21.70</paragraph></td><td valign="top"><paragraph>65</paragraph></td><td valign="top"><paragraph>14.19</paragraph></td><td valign="top"><paragraph>0.65</paragraph></td><td valign="top"><paragraph>0.47 to 0.91</paragraph></td></tr>
<tr><td valign="top"><paragraph>-All contralateral events</paragraph></td><td valign="top"><paragraph>37</paragraph></td><td valign="top"><paragraph>8.36</paragraph></td><td valign="top"><paragraph>20</paragraph></td><td valign="top"><paragraph>4.37</paragraph></td><td valign="top"><paragraph>0.52</paragraph></td><td valign="top"><paragraph>0.29 to 0.92</paragraph></td></tr>
<tr><td valign="top"><paragraph>Deaths</paragraph></td><td valign="top"><paragraph>32</paragraph></td><td valign="top"></td><td valign="top"><paragraph>28</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Uterine Malignancies<footnote id="wherry1142942728054">Updated follow-up data (median 8.1 years)</footnote></paragraph></td><td valign="top"><paragraph>4</paragraph></td><td valign="top"></td><td valign="top"><paragraph>9</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Endometrial Adenocarcinoma<footnoteref idref="wherry1142942728054"></footnoteref></paragraph></td><td valign="top"><paragraph>4</paragraph></td><td valign="top"><paragraph>0.57</paragraph></td><td valign="top"><paragraph>8</paragraph></td><td valign="top"><paragraph>1.15</paragraph></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Uterine Sarcoma<footnoteref idref="wherry1142942728054"></footnoteref></paragraph></td><td valign="top"><paragraph>0</paragraph></td><td valign="top"><paragraph>0.0</paragraph></td><td valign="top"><paragraph>1</paragraph></td><td valign="top"><paragraph>0.14</paragraph></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Second primary malignancies (other than endometrial and breast)</paragraph></td><td valign="top"><paragraph>30</paragraph></td><td valign="top"></td><td valign="top"><paragraph>29</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Stroke</paragraph></td><td valign="top"><paragraph>2</paragraph></td><td valign="top"></td><td valign="top"><paragraph>7</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
<tr><td valign="top"><paragraph>Thromboembolic events (DVT, PE)</paragraph></td><td valign="top"><paragraph>5</paragraph></td><td valign="top"></td><td valign="top"><paragraph>15</paragraph></td><td valign="top"></td><td valign="top"></td><td valign="top"></td></tr>
</tbody>
</table>